Comparison of Nine Statistical Model Based Warfarin Pharmacogenetic Dosing Algorithms Using the Racially Diverse International Warfarin Pharmacogenetic Consortium Cohort Database
暂无分享,去创建一个
Hong-Hao Zhou | Wei Zhang | Wei Zhang | Rong Liu | Rong Liu | Xi Li | Honghao Zhou | Xi Li
[1] Xiang-min Xu,et al. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients , 2009, Pharmacogenetics and genomics.
[2] Soo-Youn Lee,et al. Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation. , 2011, Clinical therapeutics.
[3] M. Rieder,et al. Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin , 2008, Clinical pharmacology and therapeutics.
[4] P. Deloukas,et al. Association of warfarin dose with genes involved in its action and metabolism , 2006, Human Genetics.
[5] M. Waye,et al. Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients , 2010, Journal of Thrombosis and Thrombolysis.
[6] S. le Cessie,et al. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. , 2011, European heart journal.
[7] M-T M Lee,et al. Prospective Study of Warfarin Dosage Requirements Based on CYP2C9 and VKORC1 Genotypes , 2008, Clinical pharmacology and therapeutics.
[8] R. Altman,et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.
[9] J. Hirsh,et al. Interactions of Warfarin with Drugs and Food , 1994, Annals of Internal Medicine.
[10] Ethem Alpaydin,et al. Introduction to Machine Learning (Adaptive Computation and Machine Learning) , 2004 .
[11] K E Liu,et al. Improvement of Adequate Use of Warfarin for the Elderly Using Decision Tree-based Approaches , 2013, Methods of Information in Medicine.
[12] Ling-Zhi Wang,et al. A warfarin‐dosing model in Asians that uses single‐nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9 , 2006, Clinical pharmacology and therapeutics.
[13] David J. C. MacKay,et al. Information Theory, Inference, and Learning Algorithms , 2004, IEEE Transactions on Information Theory.
[14] B. Horne,et al. Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation , 2007, Circulation.
[15] Christine W. Duarte,et al. High-dimensional pharmacogenetic prediction of a continuous trait using machine learning techniques with application to warfarin dose prediction in African Americans , 2011, Bioinform..
[16] D. Hunter. Gene–environment interactions in human diseases , 2005, Nature Reviews Genetics.
[17] Panos Deloukas,et al. The largest prospective warfarin-treated cohort supports genetic forecasting. , 2009, Blood.
[18] C. Ugrinowitsch,et al. Limitations of ordinary least squares models in analyzing repeated measures data. , 2004, Medicine and science in sports and exercise.
[19] F. Kamali,et al. VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. , 2012, Blood.
[20] Munir Pirmohamed,et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. , 2010, Blood.
[21] R. Habib,et al. Improved accuracy of anticoagulant dose prediction using a pharmacogenetic and artificial neural network-based method , 2014, European Journal of Clinical Pharmacology.
[22] H. Zhou,et al. Development and comparison of a new personalized warfarin stable dose prediction algorithm in Chinese patients undergoing heart valve replacement. , 2012, Die Pharmazie.
[23] Wei Zhang,et al. Effect of CYP2C9–VKORC1 interaction on warfarin stable dosage and its predictive algorithm , 2015, Journal of clinical pharmacology.
[24] Maria G. Frank. Medication Use Leading to Emergency Department Visits for Adverse Drug Events in Older Adults , 2008 .
[25] Eun-Young Kim,et al. Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement , 2009, Pharmacogenetics and genomics.
[26] A. Egberts,et al. VKORC1 and CYP2C9 Genotypes and Phenprocoumon Anticoagulation Status: Interaction Between both Genotypes Affects Dose Requirement , 2007, Clinical pharmacology and therapeutics.
[27] Massimo Buscema,et al. Prediction of optimal warfarin maintenance dose using advanced artificial neural networks. , 2014, Pharmacogenomics.
[28] R. Tibshirani,et al. An introduction to the bootstrap , 1993 .
[29] Deborah A Nickerson,et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.
[30] Wei Zhang,et al. Comparison of the predictive abilities of pharmacogenetics-based warfarin dosing algorithms using seven mathematical models in Chinese patients. , 2015, Pharmacogenomics.
[31] C. Richards,et al. Medication Use Leading to Emergency Department Visits for Adverse Drug Events in Older Adults , 2007, Annals of Internal Medicine.
[32] Zhenya Shen,et al. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients , 2007, European Journal of Clinical Pharmacology.
[33] F. Kamali,et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin , 2004, Clinical pharmacology and therapeutics.
[34] Yusheng Zhu,et al. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. , 2007, Clinical chemistry.
[35] M. Gordon,et al. Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data , 2009 .